Home/Filings/4/0001578852-26-000004
4//SEC Filing

Boulding Mark Elliott 4

Accession 0001578852-26-000004

CIK 0001070081other

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 5:20 PM ET

Size

25.2 KB

Accession

0001578852-26-000004

Insider Transaction Report

Form 4
Period: 2026-01-06
Boulding Mark Elliott
EXEC. VP AND CLO
Transactions
  • Sale

    Common Stock

    2026-01-06$76.95/sh1,739$133,816119,162 total
  • Sale

    Common Stock

    2026-01-07$77.48/sh1,503$116,452117,659 total
  • Exercise/Conversion

    Common Stock

    2026-01-07$38.10/sh+2,625$100,013120,284 total
  • Sale

    Common Stock

    2026-01-07$77.11/sh1,638$126,306118,646 total
  • Sale

    Common Stock

    2026-01-07$77.91/sh949$73,937117,697 total
  • Sale

    Common Stock

    2026-01-07$78.60/sh38$2,987117,659 total
  • Exercise/Conversion

    Common Stock

    2026-01-07$38.10/sh+751$28,613118,410 total
  • Sale

    Common Stock

    2026-01-07$77.10/sh471$36,314117,939 total
  • Sale

    Common Stock

    2026-01-07$77.92/sh269$20,960117,670 total
  • Sale

    Common Stock

    2026-01-07$78.98/sh11$869117,659 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-01-072,625751 total
    Exercise: $38.10Exp: 2032-01-06Common Stock (2,627 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-01-077510 total
    Exercise: $38.10Exp: 2032-01-06Common Stock (751 underlying)
Footnotes (8)
  • [F1]Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 3, 2025 grant of 18,000 RSUs.
  • [F2]Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs.
  • [F3]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
  • [F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.56 to $77.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F5]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.58 to $78.54 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F6]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.54 to $77.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F7]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.54 to $78.47 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F8]Currently exercisable.

Issuer

PTC THERAPEUTICS, INC.

CIK 0001070081

Entity typeother

Related Parties

1
  • filerCIK 0001578852

Filing Metadata

Form type
4
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 5:20 PM ET
Size
25.2 KB